Article info
Therapeutics
Randomised controlled trial
Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment
- Correspondence to: Professor Alexander Niessner
Waehringer Guertel 18–20, Vienna 1090, Austria; alexander.niessner{at}meduniwien.ac.at
Citation
Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment
Publication history
- First published June 27, 2012.
Online issue publication
January 17, 2013
Article Versions
- Previous version (27 June 2012).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions